Vaccine candidate to prevent infections from Acinetobacter baumannii
Official title: A Subunit Vaccine Against Acinetobacter Baumannii
Funded at Biological Mimetics, INC. · NIH-11251295 · Data updated 2026-11-12
A small SBIR project is developing a new vaccine to protect people from dangerous Acinetobacter baumannii infections.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biological Mimetics, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | December 23, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $277,962 |
| NIH project number | 5R43AI189041-02 |
| Project ID | NIH-11251295 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for AB infections, such as hospitalized patients or those with prolonged healthcare exposure.
✕Less likely to help
Patients without risk of AB exposure or those not participating in vaccine trials would likely not benefit.
What this research studies
This effort seeks to create a vaccine that trains the immune system to recognize and fight Multi-Drug Resistant Acinetobacter baumannii. Researchers will identify key immune targets, formulate a prototype vaccine, and perform initial lab and animal tests to gauge immune response and possible protection. The project uses innovative vaccine design and molecular biology tools to pick bacterial proteins that elicit strong, lasting immunity. If successful, the vaccine could reduce infections in healthcare settings and lessen antibiotic use.
Why it matters
Potential benefit: If successful, the vaccine could prevent AB infections and reduce antibiotic resistance pressure in patients and healthcare settings.
How similar studies have gone: Previous vaccine work against similar bacteria suggests that targeted antigens can induce protective immunity, though this exact AB vaccine approach is early-stage.
Where this research is happening
-
Biological Mimetics, INC.
Frederick, United States Active
Researchers
- Principal investigator: Dollery, Stephen Jeffrey — Biological Mimetics, INC.
- Study coordinator: Dollery, Stephen Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.